Crotalidae Polyvalent Immune Fab (Ovine) Antivenom Is Effective in the Neutralization of South American Viperidae Venoms in a Murine Model - 18/08/11
, David A. Tanen, MD, Tri C. Tong, MD, David P. Betten, MD, Shaun D. Carstairs, MD, Saralyn R. Williams, MD, Frank L. Cantrell, PharmD, Richard F. Clark, MD
Address for correspondence: William H. Richardson III, MD, Palmetto Poison Center, College of Pharmacy, University of South Carolina, Columbia, SC 29208; 803-777-9006, fax 803-777-6127Abstract |
Study objective |
Crotalidae polyvalent immune Fab (ovine) (CroFab; FabAV) is used in the treatment of symptomatic crotaline envenomations in North America. Unlike Antivenin (Crotalidae) Polyvalent, which is approved for treatment of crotaline envenomation in North and South America, FabAV is manufactured using only venoms from crotaline snakes native to the United States. This study was designed to evaluate the efficacy of FabAV in the neutralization of venom from 2 South American crotaline snakes: Crotalus durissus terrificus (tropical rattlesnake) and Bothrops atrox (fer-de-lance).
Methods |
A randomized, blinded, placebo-controlled murine model of intraperitoneal venom injection was used. Venom potency was determined in preliminary median lethal dose (LD50) dosing studies. Study animals were then divided into 7 groups: (1) C durissus terrificus venom (Sigma-Aldrich Co.)+FabAV, (2) C durissus terrificus venom (Sigma-Aldrich Co.)+0.9% normal saline solution, (3) C durissus terrificus venom (Biotoxins Inc.)+FabAV, (4) C durissus terrificus venom (Biotoxins Inc.)+normal saline solution, (5) B atrox venom+FabAV, (6) B atrox venom+normal saline solution, and (7) FabAV+normal saline solution. Twice the estimated LD50 was the chosen venom dose, and the amount of FabAV injected was 10 times the amount needed for venom neutralization. Statistical analysis included Fisher's exact test and log-rank testing to compare survival rates and times.
Results |
The venom LD50 was found in preliminary studies to be 0.9 mg/kg and 1.35 mg/kg for the C durissus terrificus venom obtained from Sigma-Aldrich Co. and Biotoxins Inc., respectively. The LD50 for B atrox venom was 5.0 mg/kg. All animals receiving venom only and saline solution died. Animals receiving FabAV together with either venom survived to the end of the 24-hour observation period (P<.001). Comparison of survival times between groups demonstrated a significant difference in time to death between venom-only control groups and the FabAV+venom groups (P<.001). All animals in the FabAV+normal saline solution group survived to the conclusion of the study.
Conclusion |
FabAV, when premixed with venom, decreases lethality in a murine model of intraperitoneal venom injection of the South American pit vipers, C durissus terrificus and B atrox.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| Author contributions: WHR and RFC conceived the study, design, and research. WHR and RFC obtained funding for the project. WHR coordinated data collection, analysis, and drafted the manuscript. WHR and RFC supervised the study and data collection. WHR, DAT, TCT, DPB, SDC, SRW, and FLC assisted with dosing trials, data collection, and modification of the study. WHR, DAT, SRW, and RFC participated in revision of the manuscript. WHR takes responsibility for the paper as a whole. Funding and support: Supported in part by an unrestricted grant from Altana, Inc. (Melville, NY) and antivenom donation from Protherics, Inc. (Nashville, TN). Presented at the Society of Academic Emergency Medicine annual meeting, Orlando, FL, May 2004. Reprints not available from the authors. |
Vol 45 - N° 6
P. 595-602 - giugno 2005 Ritorno al numero
Articolo precedente
- Shortness of Breath, Syncope, and Cardiac Arrest Caused by Systemic Mastocytosis
- Susan M. Rohr, Michael W. Rich, Kevin H. Silver
- Pressure-Immobilization Bandages Delay Toxicity in a Porcine Model of Eastern Coral Snake (Micrurus fulvius fulvius) Envenomation
- Benjamin T. German, Jason B. Hack, Kori Brewer, William J. Meggs
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?